Dr. Leonard G. Gomella spoke at the 24th International Prostate Cancer Update on Thursday, February 20, 2014 on “Testosterone Replacement in the Prostate Cancer Patient.” In his presentation, Dr. Gomella discusses recent clinical studies showing correlations between testosterone levels and prostate cancer and men receiving exogenous testosterone.



Keywords: testosterone replacement therapy, hypogonadal, prostate cancer, testosterone level

How to cite: Gomella, Leonard G. “Testosterone Replacement in the Prostate Cancer Patient.” Grand Rounds in Urology. January 12, 2015. Accessed Apr 2020. https://grandroundsinurology.com/prostate-cancer-leonard-g-gomella-testosterone-replacement/.


Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005 Feb;173(2):533-6. http://www.ncbi.nlm.nih.gov/pubmed/15643240

Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010 Jul 8;363(2):109-22. http://www.ncbi.nlm.nih.gov/pubmed/20592293

Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006 Jun;91(6):1995-2010 http://www.ncbi.nlm.nih.gov/pubmed/16720669

Carroll P, Coley C, McLeod D, et al. Prostate-specific antigen best practice policy–part I: early detection and diagnosis of prostate cancer. Urology. 2001 Feb;57(2):217-24. http://www.ncbi.nlm.nih.gov/pubmed/11182324

Conners WP 3rd, Morgentaler A. The evaluation and management of testosterone deficiency: the new frontier in urology and men’s health. Curr Urol Rep. 2013 Dec;14(6):557-64. http://www.ncbi.nlm.nih.gov/pubmed/23999611

Dandona P, Rosenberg MT. A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract. 2010 May;64(6):682-96. http://www.ncbi.nlm.nih.gov/pubmed/20518947

English KM, Steeds RP, Jones TH, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation. 2000 Oct 17;102(16):1906-11. http://www.ncbi.nlm.nih.gov/pubmed/11034937

English KM, Mandour O, Steeds RP, et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J. 2000 Jun;21(11):890-4. http://www.ncbi.nlm.nih.gov/pubmed/10806012

Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014 Jan 29;9(1):e85805. http://www.ncbi.nlm.nih.gov/pubmed/24489673

Gooren LJ, Behre HM, Saad F,  et al. Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research. Aging Male. 2007 Dec;10(4):173-81 http://www.ncbi.nlm.nih.gov/pubmed/18033626

Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007 Jan;82(1):29-39 http://www.ncbi.nlm.nih.gov/pubmed/17285783

Hak AE, Witteman JC, de Jong FH, et al.  Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. 2002 Aug;87(8):3632-9. http://www.ncbi.nlm.nih.gov/pubmed/12161487

Hijazi RA, Cunningham GR. Andropause: is androgen replacement therapy indicated for the aging male? Annu Rev Med. 2005;56:117-37. http://www.ncbi.nlm.nih.gov/pubmed/15660505

Jannini EA, Gravina GL, Morgentaler A, et al. Is testosterone a friend or a foe of the prostate? J Sex Med. 2011 Apr;8(4):946-55. http://www.ncbi.nlm.nih.gov/pubmed/21457469

Kaplan AL, Hu JC. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes. Urology. 2013 Aug;82(2):321-6. http://www.ncbi.nlm.nih.gov/pubmed/23706552

Khera M, Crawford D, Morales A, et al. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol. 2014 Jan;65(1):115-23. http://www.ncbi.nlm.nih.gov/pubmed/24011426

Khera M, Grober ED, Najari B, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009 Apr;6(4):1165-70. http://www.ncbi.nlm.nih.gov/pubmed/19207277

Maggi M, Schulman C, Quinton R, et al. The burden of testosterone deficiency syndrome in adult men: economic and quality-of-life impact. J Sex Med. 2007 Jul;4(4 Pt 1):1056-69. http://www.ncbi.nlm.nih.gov/pubmed/17627750

McNicholas TA, Dean JD, Mulder H, et al. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int. 2003 Jan;91(1):69-74. http://www.ncbi.nlm.nih.gov/pubmed/12614254

Miner MM, Sadovsky R. Evolving issues in male hypogonadism: evaluation, management, and related comorbidities. Cleve Clin J Med. 2007 May;74 Suppl 3:S38-46. http://www.ncbi.nlm.nih.gov/pubmed/17549824

Morgentaler A, Bruning CO 3rd, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA. 1996 Dec 18;276(23):1904-6. http://www.ncbi.nlm.nih.gov/pubmed/8968017

Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006 Jul;60(7):762-9. http://www.ncbi.nlm.nih.gov/pubmed/16846397

Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013 Oct 21;169(6):725-33. http://www.ncbi.nlm.nih.gov/pubmed/23999642

Raynaud JP. Prostate cancer risk in testosterone-treated men. J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):261-6. http://www.ncbi.nlm.nih.gov/pubmed/17113983

Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004 Jan 29;350(5):482-92. http://www.ncbi.nlm.nih.gov/pubmed/14749457

Shelton JB, Rajfer J. Androgen deficiency in aging and metabolically challenged men. Urol Clin North Am. 2012 Feb;39(1):63-75.  http://www.ncbi.nlm.nih.gov/pubmed/22118346

Shores MM, Matsumoto AM, Sloan KL, et al. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006 Aug 14-28;166(15):1660-5. http://www.ncbi.nlm.nih.gov/pubmed/16908801

Shores MM, Smith NL, Forsberg CW, et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012 Jun;97(6):2050-8. http://www.ncbi.nlm.nih.gov/pubmed/22496507

Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with lowtestosterone levels. JAMA. 2013 Nov 6;310(17):1829-36. http://www.ncbi.nlm.nih.gov/pubmed/24193080

Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl. 2009 Jan-Feb;30(1):1-9. http://www.ncbi.nlm.nih.gov/pubmed/18772485

Webb CM, McNeill JG, Hayward CS, et al. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation. 1999 Oct 19;100(16):1690-6. http://www.ncbi.nlm.nih.gov/pubmed/10525487

Yeap BB, Alfonso H, Chubb SA, et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. J Clin Endocrinol Metab. 2014 Jan;99(1):E9-18. http://www.ncbi.nlm.nih.gov/pubmed/24257908